161 related articles for article (PubMed ID: 37011336)
21. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
Park R; Saeed A
NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
[TBL] [Abstract][Full Text] [Related]
22. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
23. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
Li S; Na R; Li X; Zhang Y; Zheng T
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
[TBL] [Abstract][Full Text] [Related]
24. [Neoadjuvant immunotherapy for colorectal cancer].
Pei JP; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
[TBL] [Abstract][Full Text] [Related]
25. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
Choucair K; Radford M; Bansal A; Park R; Saeed A
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
[TBL] [Abstract][Full Text] [Related]
26. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
Liu N; Shan F; Ma M
Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927
[TBL] [Abstract][Full Text] [Related]
28. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Liang T; Tong W; Ma S; Chang P
Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
[TBL] [Abstract][Full Text] [Related]
29. Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer.
Hulo P; Touchefeu Y; Cauchin E; Archambeaud I; Chapelle N; Bossard C; Bennouna J
Clin Colorectal Cancer; 2020 Dec; 19(4):e183-e188. PubMed ID: 32703755
[No Abstract] [Full Text] [Related]
30. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
31. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
33. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
34. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
35. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
36. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
[TBL] [Abstract][Full Text] [Related]
37. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
Ricci AD; Rizzo A; Brandi G
Cancer Control; 2020; 27(3):1073274820948047. PubMed ID: 32806956
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of metastatic colorectal cancer with synchronous
Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
[TBL] [Abstract][Full Text] [Related]
40. [Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation].
Wu ZH; Cheng Y; Hu HB; Zhang JW; Deng YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):416-423. PubMed ID: 38644248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]